WO2011055395A1 - Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections - Google Patents
Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections Download PDFInfo
- Publication number
- WO2011055395A1 WO2011055395A1 PCT/IT2009/000499 IT2009000499W WO2011055395A1 WO 2011055395 A1 WO2011055395 A1 WO 2011055395A1 IT 2009000499 W IT2009000499 W IT 2009000499W WO 2011055395 A1 WO2011055395 A1 WO 2011055395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- battery
- light source
- light
- switch
- capsule
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0609—Stomach and/or esophagus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0653—Organic light emitting diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Definitions
- the present invention relates to the field of devices for the therapeutic treatment of patients, and in particular to the field of devices for treating H. pylori infections. STATE OF THE ART
- H. pylori is a bacterium considered one of the causing agents of inflammation and ulcerous lesions of the stomach and duodenum; in particular, infection by this bacterium is associated to chronic gastritis, gastro-duodenal ulcer, cancer and gastric lymphoma.
- H. pylori infection is treated by using a pharmacological eradication therapy, generally consisting of the association of an antisecretion drug and two and/or three antibiotics.
- a pharmacological eradication therapy generally consisting of the association of an antisecretion drug and two and/or three antibiotics.
- M. R. Hamblin et al. announced in "Antimicrobial Agents and Chemotherapy", July 2005, p. 2822-2827, that H. pylori is sensitive to the action of visible light and suggested the use of photodynamic therapy for in vivo treatment of infected patients.
- Apparatuses consisting of capsules capable of illuminating internal organs for diagnostic purposes are known, such as for example from patent US 2007/0238921 , but the devices of the prior art do not contemplate the possibility of providing targeted lighting for the treatment of H. pylori bacteria colonies.
- the light source provided to the device is optimized in terms of wavelength and intensity to promote the energizing of exogenous fluorophores (e.g. quantum dots), thus being inappropriate for therapeutic use aimed at energizing endogenous molecules, such as porphyrins.
- Lighting is highly directional, and thus only illuminates a very limited portion of the gastric mucous membrane ; the presence of the camera and transmitter is unnecessary for the purposes of the present invention, in addition to consuming energy which could otherwise be used for energizing the porphyrins.
- the light energy used to energize fluorescence is much lower than that needed for obtaining a photodynamic effect, as in this case.
- Fig.1 shows a diagram of an inner structure of a first preferred embodiment of the device according to the present invention.
- Fig.1 shows a diagram of the inner structure of a second preferred embodiment of the device according to the present invention.
- An ingestible device for illuminating the gastric cavity of the stomach for therapeutic purposes comprising: an external casing 1 ; at least one punctiform light source; a battery 3; a power supply circuit associated to said battery and to said at least one punctiform light source; a switch 10 associated to said power supply source; at least one semi-reflecting mirror 8 associated to said at least one punctiform light source and adapted to produce a light emission extended over most of the solid angle, said outer casing 1 being transparent to radiation emitted by said at least one punctiform light source and made of non-digestible material.
- the present invention allows to overcome the above-described problems by means of an ingestible capsule provided with lighting means adapted to illuminate the desired organ (in this case, the stomach and the duodenum).
- the purpose of the capsule is to provide high-intensity light as uniform as possible for photo-therapeutic purposes.
- the device object of the present invention comprises:
- At least one punctiform light source preferably consisting of a LED 6;
- At least one semi-reflecting mirror 8 associated to said at least one punctiform light source and adapted to promote a light emission extended over most of the solid angle;
- said external casing 1 is transparent to radiation emitted by said at least one punctiform light source and is made of non-digestible material, e.g. polymethyl methacrylate (PMMA), adapted to promote the adhesion thereof onto the stomach wall and preferably coated with a layer of slippery material adapted to promote the its swallowing and be rapidly dissolved by gastric acid.
- Said outer casing 1 may further be adapted to contain a mixture of air enriched with oxygen at pressure higher than atmospheric pressure so as to optimize the operation of said battery 3.
- Said at least one light source is of the type adapted to emit appropriate wavelengths, preferably 405nm and 630nm; furthermore, it comprises at least one high-intensity LED positioned immediately underneath said transparent casing 1 and about the battery 3 from which they take the required power.
- Said battery 3 should contain sufficient energy for powering the LEDs for at least .20 - 30 minutes (the average transit time in the gastric antrum).
- Said switch 10, associated to said battery 3, is preferably timed 0, so as to allow a delayed lighting and allow the tablet to be still "off' when it is swallowed and turned on later.
- Said ignition should preferably occur within a time either comparable to or lower than the average time required by the capsule to reach the stomach (e.g. 10 - 60 seconds).
- the battery Given the optimal geometric configuration for promoting swallowing (cylindrical shape of the capsule with rounded side surfaces), the battery will be positioned in the middle with the LEDs around it. Appropriately shaped semi-transparent (reflecting) mirrors 8 will be inserted within said capsule in order to improve radiation. In this manner, the wavelengths of the reflected light 13 are the same as those of the light 12 which directly crosses the reflectors.
- said capsule is made in oxygen enriched atmosphere, and possibly with inner pressure higher than atmospheric pressure to allow use of a zinc-air battery.
- the battery may be provided with an appropriate casing 4 containing compressed air and such to guarantee optimal operating conditions, in addition to preventing the release of gas contained therein.
- the zinc-air battery is indeed today one with the highest KWh/m 3 ratio with regards to the delivered energy per unit of volume of the battery.
- batteries Alternatively to zinc : air batteries, other types of batteries may be used, e.g. lithium type batteries.
- the light transmitted by LED sources is in part transmitted 12 by the semi- transparent mirrors 8 and in part reflected 13, thus crosses the casing of the capsule 1 and strikes the target constituted by the H. pylori bacterium.
- the light is in particular absorbed by the present porphyrin molecules, thus performing the desired therapeutic action.
- the external sizes of the capsule according to the present invention are such to easily pass through the entire digestive tract, and will be preferably coated with a biocompatible substance also having a sealing function so as to prevent the release of potentially toxic substances contained within the capsule.
- the capsule according to the present invention will have a diameter smaller than or equal to 12 mm and a length smaller than or equal to 26 mm.
- Plastic material coating is preferred, providing that it is transparent to the radiation emitted by the light sources within the capsule itself. If preferred, said coating will be chosen from the materials having diffusive light emission features, according to an emission as distributed as possible across the entire solid angle and not directly outwards in few, very precise directions. The purpose is indeed to be able to invest most surface of the inner wall of the stomach with light.
- the coating considering the requirements of non-toxicity, may be made so as to promote swallowing but at the same time loose this feature of "slipperiness" as soon as it reaches the stomach.
- the capsule will be provided with an outer coating (which is eliminated by contact with the liquid physiologically present in the gastric lumen) making it slipp.er ⁇ and/easy_to_swal!ow.,..an ⁇
- the therapeutic treatment may be preceded by ingesting a specific powder and water which leads to the rapid formation of a gel; such a gel has the purpose of promoting distension of the stomach and slowing down the capsule in the gastric lumen.
- a gel has the purpose of promoting distension of the stomach and slowing down the capsule in the gastric lumen.
- the capsule is swallowed immediately after administration of the gel (1-2 minutes).
- the gel which must be transparent to the light emitted by the capsule has the further purpose of scattering the emitted light so as to illuminate the widest surface possible.
- the capsule according to the invention is adapted to emit visible light radiation with emission spectrum characterized by either one or two peaks, i.e. by a one- color emission (red or violet) or by a two-color emission (red and violet) at the same time.
- Punctiform light sources preferably used in the device according to the present invention consist of LED, OLED or laser diodes.
- Laser diodes have higher efficiency but offer unnecessary performances for the purpose of the present invention, performances which may have negative effect on the costs of the device. Furthermore, laser diodes have a much more directed emission and thus unfavorable for the purpose of the present invention.
- OLEDs are very promising light energy sources, although they are now intrinsically not very bright, i.e. the density of light energy emitted per solid angle unit is very low, and currently with efficiency lower than that of LEDs.
- the emitted spectrum will have emission peak spectrum width about 20 nm (FWHM) and an emission wavelength centered in red of about 650 nm and in violet of about 405 nm.
- the light emission lobe must be extended across the widest possible solid angle so as to allow a poorly directed emission. LEDs (both single and in form of LED arrays) with an emission lobe which ranges from +/- 30 degrees to +/- 60 degrees
- the emitted light intensity (Watt/cm 2 ) must be as high as possible, compatibly with non-dangerous levels for healthy tissue; the total energy emitted on the solid global emission angle, during the illumination time, should be such to perform an effective cytotoxic action (e.g. values of 30J / cm 2 ).
- the light source of the device according to the present invention must be turned on immediately after ingestion by activating said switch 10, associated to said battery 3, e.g. by using a miniature switch 1 1 actuatable by means of pressure on the outer surface of the capsule or simply by screwing the two half-portions of the capsule.
- the capsule may be turned on from the outside, e.g. by means of appropriate reception means included in the capsule and adapted to pick up a remote power- on signal.
- the capsule should be provided with a specific electronic circuitry arranged inside it and provided with the following features: having low power consumption, being such circuitry powered by the battery inside the capsule; having lower heat dispersion, so as not to cause potential damage to the tissues and to the capsule itself; and being as miniaturized as possible.
- the capsule may be further equipped with a sensor for signally entrance into the intestine and either switch it off or be provided with a remote power-off system similar to that described above with regards to power-on.
- the tablet Due to heat dispersion of part of the energy used by the LEDs (and by the circuitry integrated in the tablet itself), it may be necessary to provide the tablet with a heat sink system.
- the latter preferably of passive type, has the purpose of decreasing the temperature of the tablet so as to make it as uniform with the surrounding ambient temperature (stomach cavity, intestine) as possible.
- a gelatinous substance mixed with water and transparent to the radiation emitted by the capsule may be introduced into the patient's stomach, for the purpose of distending the plicae gastricae, thus favoring uniformity of illumination and efficacy of the illuminating capsule according to the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
The light capsule object of the present invention is an ingestible device designed to illuminate the gastric cavity of the stomach for therapeutic purposes directed against Helicobacter pylori (H. pylori) bacteria. It comprises: a casing transparent to visible light, in turn containing punctiform light sources, preferably constituted by LEDs, positioned immediately under said casing and capable of emitting light at appropriate wavelength bands (preferably 405nm and 630nm); a battery, adapted to power the LED sources for approximately 20 - 30 minutes (the average transit time in the stomach); a switch which allows a delayed power on and allows the tablet to be still "off" when it is swallowed. The light emitted by the capsule strikes the H. pylori bacteria anchored on the gastric wall. The light radiation is preferentially absorbed by molecules of porphyrin produced by the bacterium which works as photosensitizing agent by inducing the formation of cytotoxic molecular species.
Description
"Ingestible capsule for treating gastric infections, in particular for treating H. pylori infections"
FIELD OF THE INVENTION
The present invention relates to the field of devices for the therapeutic treatment of patients, and in particular to the field of devices for treating H. pylori infections. STATE OF THE ART
As known, H. pylori is a bacterium considered one of the causing agents of inflammation and ulcerous lesions of the stomach and duodenum; in particular, infection by this bacterium is associated to chronic gastritis, gastro-duodenal ulcer, cancer and gastric lymphoma.
H. pylori infection is treated by using a pharmacological eradication therapy, generally consisting of the association of an antisecretion drug and two and/or three antibiotics. M. R. Hamblin et al. announced in "Antimicrobial Agents and Chemotherapy", July 2005, p. 2822-2827, that H. pylori is sensitive to the action of visible light and suggested the use of photodynamic therapy for in vivo treatment of infected patients.
Apparatuses consisting of capsules capable of illuminating internal organs for diagnostic purposes are known, such as for example from patent US 2007/0238921 , but the devices of the prior art do not contemplate the possibility of providing targeted lighting for the treatment of H. pylori bacteria colonies.
Indeed, in the aforesaid patent, the light source provided to the device is optimized in terms of wavelength and intensity to promote the energizing of exogenous fluorophores (e.g. quantum dots), thus being inappropriate for therapeutic use aimed at energizing endogenous molecules, such as porphyrins. Lighting is highly directional, and thus only illuminates a very limited portion of the gastric mucous membrane ; the presence of the camera and transmitter is unnecessary for the purposes of the present invention, in addition to consuming energy which could otherwise be used for energizing the porphyrins. Furthermore, the light energy used to energize fluorescence is much lower than that needed for obtaining a photodynamic effect, as in this case.
It would thus be extremely useful to have a device capable of radiating high-
intensity light at an appropriate wavelength onto the stomach walls colonized by H. pylori bacterium so as to prevent proliferation and thus promote elimination.
BRIEF DESCRIPTION OF THE FIGURES
Fig.1 shows a diagram of an inner structure of a first preferred embodiment of the device according to the present invention.
Fig.1 shows a diagram of the inner structure of a second preferred embodiment of the device according to the present invention.
DISCLOSURE OF THE INVENTION
An ingestible device for illuminating the gastric cavity of the stomach for therapeutic purposes comprising: an external casing 1 ; at least one punctiform light source; a battery 3; a power supply circuit associated to said battery and to said at least one punctiform light source; a switch 10 associated to said power supply source; at least one semi-reflecting mirror 8 associated to said at least one punctiform light source and adapted to produce a light emission extended over most of the solid angle, said outer casing 1 being transparent to radiation emitted by said at least one punctiform light source and made of non-digestible material. DETAILED DESCRIPTION OF THE INVENTION
The present invention allows to overcome the above-described problems by means of an ingestible capsule provided with lighting means adapted to illuminate the desired organ (in this case, the stomach and the duodenum).
The purpose of the capsule is to provide high-intensity light as uniform as possible for photo-therapeutic purposes.
With reference to Fig. 1 , the device object of the present invention comprises:
an external casing 1 ;
a battery 3;
at least one punctiform light source, preferably consisting of a LED 6;
a„power_supply-_cir.cuit__assQciated_Jo___said^battery_and Jo__said_.at Jeast_one_... punctiform light source;
at least one semi-reflecting mirror 8 associated to said at least one punctiform light source and adapted to promote a light emission extended over most of the solid angle;
a switch 10 associated to said power supply circuit.
In further detail, said external casing 1 is transparent to radiation emitted by said at least one punctiform light source and is made of non-digestible material, e.g. polymethyl methacrylate (PMMA), adapted to promote the adhesion thereof onto the stomach wall and preferably coated with a layer of slippery material adapted to promote the its swallowing and be rapidly dissolved by gastric acid. Said outer casing 1 may further be adapted to contain a mixture of air enriched with oxygen at pressure higher than atmospheric pressure so as to optimize the operation of said battery 3.
Said at least one light source is of the type adapted to emit appropriate wavelengths, preferably 405nm and 630nm; furthermore, it comprises at least one high-intensity LED positioned immediately underneath said transparent casing 1 and about the battery 3 from which they take the required power. Said battery 3 should contain sufficient energy for powering the LEDs for at least .20 - 30 minutes (the average transit time in the gastric antrum).
Said switch 10, associated to said battery 3, is preferably timed 0, so as to allow a delayed lighting and allow the tablet to be still "off' when it is swallowed and turned on later. Said ignition should preferably occur within a time either comparable to or lower than the average time required by the capsule to reach the stomach (e.g. 10 - 60 seconds).
Given the optimal geometric configuration for promoting swallowing (cylindrical shape of the capsule with rounded side surfaces), the battery will be positioned in the middle with the LEDs around it. Appropriately shaped semi-transparent (reflecting) mirrors 8 will be inserted within said capsule in order to improve radiation. In this manner, the wavelengths of the reflected light 13 are the same as those of the light 12 which directly crosses the reflectors.
In a preferred embodiment of the present invention, said capsule is made in oxygen enriched atmosphere, and possibly with inner pressure higher than atmospheric pressure to allow use of a zinc-air battery. For this purpose, the battery may be provided with an appropriate casing 4 containing compressed air and such to guarantee optimal operating conditions, in addition to preventing the release of gas contained therein. The zinc-air battery is indeed today one with the highest KWh/m3 ratio with regards to the delivered energy per unit of volume of the
battery.
Alternatively to zinc:air batteries, other types of batteries may be used, e.g. lithium type batteries.
The light transmitted by LED sources is in part transmitted 12 by the semi- transparent mirrors 8 and in part reflected 13, thus crosses the casing of the capsule 1 and strikes the target constituted by the H. pylori bacterium.
Within the bacterium struck by light radiation emitted by the capsule according to the present invention, the light is in particular absorbed by the present porphyrin molecules, thus performing the desired therapeutic action.
The external sizes of the capsule according to the present invention are such to easily pass through the entire digestive tract, and will be preferably coated with a biocompatible substance also having a sealing function so as to prevent the release of potentially toxic substances contained within the capsule. Preferably, the capsule according to the present invention will have a diameter smaller than or equal to 12 mm and a length smaller than or equal to 26 mm.
Plastic material coating is preferred, providing that it is transparent to the radiation emitted by the light sources within the capsule itself. If preferred, said coating will be chosen from the materials having diffusive light emission features, according to an emission as distributed as possible across the entire solid angle and not directly outwards in few, very precise directions. The purpose is indeed to be able to invest most surface of the inner wall of the stomach with light.
Furthermore, the coating, considering the requirements of non-toxicity, may be made so as to promote swallowing but at the same time loose this feature of "slipperiness" as soon as it reaches the stomach.
Preferably, the capsule will be provided with an outer coating (which is eliminated by contact with the liquid physiologically present in the gastric lumen) making it slipp.er^and„easy_to_swal!ow.,..an^
adhesion onto the walls of the stomach.
For example, in order to obtain optimal capsule positioning and lighting conditions, the therapeutic treatment may be preceded by ingesting a specific powder and water which leads to the rapid formation of a gel; such a gel has the purpose of promoting distension of the stomach and slowing down the capsule in the gastric
lumen. The capsule is swallowed immediately after administration of the gel (1-2 minutes). The gel which must be transparent to the light emitted by the capsule has the further purpose of scattering the emitted light so as to illuminate the widest surface possible.
The capsule according to the invention is adapted to emit visible light radiation with emission spectrum characterized by either one or two peaks, i.e. by a one- color emission (red or violet) or by a two-color emission (red and violet) at the same time.
This need is related to that fact that red light has a better penetration in tissues but less bactericide efficiency, while violet light on the other hand has a lower penetration but a better cytotoxic efficacy.
Punctiform light sources preferably used in the device according to the present invention consist of LED, OLED or laser diodes. Laser diodes have higher efficiency but offer unnecessary performances for the purpose of the present invention, performances which may have negative effect on the costs of the device. Furthermore, laser diodes have a much more directed emission and thus unfavorable for the purpose of the present invention. OLEDs are very promising light energy sources, although they are now intrinsically not very bright, i.e. the density of light energy emitted per solid angle unit is very low, and currently with efficiency lower than that of LEDs.
The emitted spectrum will have emission peak spectrum width about 20 nm (FWHM) and an emission wavelength centered in red of about 650 nm and in violet of about 405 nm.
The light emission lobe must be extended across the widest possible solid angle so as to allow a poorly directed emission. LEDs (both single and in form of LED arrays) with an emission lobe which ranges from +/- 30 degrees to +/- 60 degrees
_exist_QnJhe_marke_t_for_this_purpose..
In order to obtain the desired light emission, several LED sources appropriately arranged in the capsule must be used, so as to partially overlap the emission lobes and cover the widest possible solid angle.
The emitted light intensity (Watt/cm2) must be as high as possible, compatibly with non-dangerous levels for healthy tissue; the total energy emitted on the solid
global emission angle, during the illumination time, should be such to perform an effective cytotoxic action (e.g. values of 30J / cm2).
The light source of the device according to the present invention must be turned on immediately after ingestion by activating said switch 10, associated to said battery 3, e.g. by using a miniature switch 1 1 actuatable by means of pressure on the outer surface of the capsule or simply by screwing the two half-portions of the capsule. Alternatively, in a further preferred embodiment of the present invention, the capsule may be turned on from the outside, e.g. by means of appropriate reception means included in the capsule and adapted to pick up a remote power- on signal. In order to implement the aforesaid functions, the capsule should be provided with a specific electronic circuitry arranged inside it and provided with the following features: having low power consumption, being such circuitry powered by the battery inside the capsule; having lower heat dispersion, so as not to cause potential damage to the tissues and to the capsule itself; and being as miniaturized as possible.
The capsule may be further equipped with a sensor for signally entrance into the intestine and either switch it off or be provided with a remote power-off system similar to that described above with regards to power-on.
Due to heat dispersion of part of the energy used by the LEDs (and by the circuitry integrated in the tablet itself), it may be necessary to provide the tablet with a heat sink system. The latter, preferably of passive type, has the purpose of decreasing the temperature of the tablet so as to make it as uniform with the surrounding ambient temperature (stomach cavity, intestine) as possible.
In order to release light energy for eliminating the highest possible number of bacteria (H. pylori), several tablets may be swallowed in time or the treatment may be extended in time (e.g. over 1-2 weeks).
Furthermore, preferably, before swallowing the device, a gelatinous substance mixed with water and transparent to the radiation emitted by the capsule may be introduced into the patient's stomach, for the purpose of distending the plicae gastricae, thus favoring uniformity of illumination and efficacy of the illuminating capsule according to the present invention.
Claims
1. Ingestible device for illuminating the gastric cavity of the stomach for therapeutic purposes comprising: a external casing (1 ); at least one punctiform light source; a battery (3); a power supply circuit associated to said battery and to said at least one punctiform light source; a switch (10) associated to said power supply source; at least one semi-reflecting mirror (8) associated to said at least one punctiform light source and adapted to produce a light emission extended on most of the solid angle, said outer casing (1 ) being transparent to radiation emitted by said at least one punctiform light source and made of non-digestible material.
2. A device according to claim 1 , characterized in that said outer casing (1 ) is coated by a surface layer of slippery material adapted to promote its swallowing and be rapidly dissolved by gastric liquids.
3. A device according to claims 1-2, characterized in that said outer casing (1 ) is further adapted to contain a mixture of air enriched with oxygen at pressure higher than atmospheric pressure.
4. A device according to claims 1-3, characterized in that it comprises a further coating layer, underneath said slippery material surface layer and adapted to promote the adhesion of said device to the stomach wall.
5. A device according to claims 1-4, characterized in that said at least one punctiform light source is of the type adapted to emit appropriate wavelength bands comprising values of 405 nm and 630 nm.
6. A device according to claims 1-5, characterized in that said at least one punctiform light source is such to emit a emission lobe of width comprised from +/- 30 degrees to +/-60 degrees.
7. A device according to claims 1-6, characterized in that said at least one punctiform light source is chosen from the group comprising LEDs, OLEDs and laser diodes.
8. A device according to claims 1-7, characterized in that said outer casing (1 ) is made of polymethyl methacrylate (PMMA).
9. A device according to claims 1-8, characterized in that said battery (3) is of the lithium type.
10. A device according to claims 1-8, characterized in that said battery (3) is of the zinc-air type.
11. A device according to claim 10, characterized in that said battery (3) is provided with an appropriate casing (4) adapted to contain air enriched with oxygen at pressure higher than atmospheric pressure.
12. A device according to claims 1-11 , characterized in that said switch (10), associated to said battery (3), is further associated to a miniaturized switch (11 ) operatable by means of pressure on the outer surface of said device or by means of simple screwing of two semi-portions of said device.
13. A device according to claims 1-12, characterised in that said switch (10) is a timed switch so as to allow a delayed power-on to allow said device to be swallowed still off and turned on later.
14. A device according to claims 1-13, characterized in that said switch (10) can be remotely operated.
15. A device according to claim 1-14, characterised by a diameter equal to or smaller than 2 mm and by a length shorter than or equal to 26 mm.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2009/000499 WO2011055395A1 (en) | 2009-11-06 | 2009-11-06 | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
US13/508,195 US9138593B2 (en) | 2009-11-06 | 2009-11-06 | Ingestible capsule for treating gastric infections, in particular for treating H. pylori infections |
EP20090820080 EP2496306B1 (en) | 2009-11-06 | 2009-11-06 | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2009/000499 WO2011055395A1 (en) | 2009-11-06 | 2009-11-06 | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011055395A1 true WO2011055395A1 (en) | 2011-05-12 |
Family
ID=42104328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2009/000499 WO2011055395A1 (en) | 2009-11-06 | 2009-11-06 | Ingestible capsule for treating gastric infections, in particular for treating h. pylori infections |
Country Status (3)
Country | Link |
---|---|
US (1) | US9138593B2 (en) |
EP (1) | EP2496306B1 (en) |
WO (1) | WO2011055395A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014147497A1 (en) * | 2013-03-19 | 2014-09-25 | Medlight S.A. | Medical device for illuminating cavities of complex shapes |
IT201600129679A1 (en) * | 2016-12-21 | 2018-06-21 | Probiomedica S R L | Ingestible capsule for the phototherapeutic treatment of infections |
US10300296B2 (en) | 2010-03-17 | 2019-05-28 | Photopill Medical Ltd. | Capsule phototherapy |
US10357661B2 (en) | 2011-09-30 | 2019-07-23 | Percuvision, Llc | Medical device and method for internal healing and antimicrobial purposes |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190052241A (en) * | 2017-11-08 | 2019-05-16 | 서울바이오시스 주식회사 | Sterilizing device |
CN109567757B (en) * | 2018-12-29 | 2020-01-21 | 深圳普门科技股份有限公司 | Hp micro-detection and treatment integrated capsule based on color detection |
CN113660978A (en) * | 2019-03-04 | 2021-11-16 | 光疗胶囊医学有限公司 | Method and apparatus for gut microbiota manipulation |
KR102106244B1 (en) * | 2019-10-30 | 2020-05-04 | 한국광기술원 | Capsule type photodynamic therapy apparatus with anchor |
US11800851B2 (en) * | 2019-12-29 | 2023-10-31 | Brian Michael Coyle | Light capsule |
CA3166610A1 (en) * | 2020-01-31 | 2021-08-05 | Masoud TAHGHIGHI JAFARZADEH | An ingestible therapeutic device for the treatment of gastritis |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003210395A (en) * | 2002-01-22 | 2003-07-29 | Olympus Optical Co Ltd | Capsule-type medical apparatus |
US20040039242A1 (en) * | 2002-04-02 | 2004-02-26 | Seedling Enterprises, Llc | Apparatus and methods using visible light for debilitating and/or killing microorganisms within the body |
US20050192478A1 (en) * | 2004-02-27 | 2005-09-01 | Williams James P. | System and method for endoscopic optical constrast imaging using an endo-robot |
US20060167531A1 (en) * | 2005-01-25 | 2006-07-27 | Michael Gertner | Optical therapies and devices |
EP1714607A1 (en) * | 2005-04-22 | 2006-10-25 | Given Imaging Ltd. | Device, system and method for motility measurement and analysis |
WO2008012701A1 (en) * | 2006-07-24 | 2008-01-31 | Philips Intellectual Property And Standards Gmbh | Capsule camera with variable illumination of the surrounding tissue |
US20080039768A1 (en) * | 2006-08-10 | 2008-02-14 | Medtronic, Inc. | Implantable devices with photocatalytic surfaces for treating hydrocephalus |
US20090137876A1 (en) * | 2007-10-19 | 2009-05-28 | Bioscopix, Inc. | Diagnostic capsule with peripheral imaging |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3443728C2 (en) * | 1984-11-30 | 1987-02-12 | C. Reichert Optische Werke Ag, Wien | Microscope photometer |
IL108352A (en) * | 1994-01-17 | 2000-02-29 | Given Imaging Ltd | In vivo video camera system |
US5838247A (en) * | 1997-04-01 | 1998-11-17 | Bladowski; Witold S. | Solid state light system |
US8636648B2 (en) * | 1999-03-01 | 2014-01-28 | West View Research, Llc | Endoscopic smart probe |
US6187021B1 (en) * | 1999-12-23 | 2001-02-13 | Becker Wim | Ear cleaning portable rotary device |
IL141907A0 (en) * | 2000-03-08 | 2002-03-10 | Given Imaging Ltd | A device and system for in vivo imaging |
JP2003260025A (en) * | 2002-03-08 | 2003-09-16 | Olympus Optical Co Ltd | Capsule endoscope |
US7129210B2 (en) * | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
FR2862809B1 (en) * | 2003-11-20 | 2006-03-10 | Crouzet Automatismes | MICROSWITCH |
US20050137468A1 (en) * | 2003-12-18 | 2005-06-23 | Jerome Avron | Device, system, and method for in-vivo sensing of a substance |
US7922655B2 (en) * | 2004-07-02 | 2011-04-12 | Osaka University | Endoscope attachment and endoscope |
EP1989751B1 (en) * | 2006-02-17 | 2012-05-02 | E.M.W. Energy Co., Ltd. | Cylinder type zin-air cell and method for priducing the same |
CN101681013B (en) * | 2007-06-12 | 2012-09-26 | 奥林巴斯株式会社 | Optical element, optical system, and endoscope using same |
ES2395877T3 (en) * | 2007-06-19 | 2013-02-15 | Rynel, Inc. | Materials comprising water soluble polymer particles and methods for preparing and using them |
US8515507B2 (en) * | 2008-06-16 | 2013-08-20 | Given Imaging Ltd. | Device and method for detecting in-vivo pathology |
US20120136209A1 (en) * | 2009-08-05 | 2012-05-31 | Tel Hashomer Medical Research Infrastructure And Services, Ltd. | Methods and devices for providing information useful in the diagnosis of abnormalities of the gastrointestinal tract |
-
2009
- 2009-11-06 EP EP20090820080 patent/EP2496306B1/en active Active
- 2009-11-06 US US13/508,195 patent/US9138593B2/en not_active Expired - Fee Related
- 2009-11-06 WO PCT/IT2009/000499 patent/WO2011055395A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003210395A (en) * | 2002-01-22 | 2003-07-29 | Olympus Optical Co Ltd | Capsule-type medical apparatus |
US20040039242A1 (en) * | 2002-04-02 | 2004-02-26 | Seedling Enterprises, Llc | Apparatus and methods using visible light for debilitating and/or killing microorganisms within the body |
US20050192478A1 (en) * | 2004-02-27 | 2005-09-01 | Williams James P. | System and method for endoscopic optical constrast imaging using an endo-robot |
US20060167531A1 (en) * | 2005-01-25 | 2006-07-27 | Michael Gertner | Optical therapies and devices |
EP1714607A1 (en) * | 2005-04-22 | 2006-10-25 | Given Imaging Ltd. | Device, system and method for motility measurement and analysis |
WO2008012701A1 (en) * | 2006-07-24 | 2008-01-31 | Philips Intellectual Property And Standards Gmbh | Capsule camera with variable illumination of the surrounding tissue |
US20080039768A1 (en) * | 2006-08-10 | 2008-02-14 | Medtronic, Inc. | Implantable devices with photocatalytic surfaces for treating hydrocephalus |
US20090137876A1 (en) * | 2007-10-19 | 2009-05-28 | Bioscopix, Inc. | Diagnostic capsule with peripheral imaging |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10300296B2 (en) | 2010-03-17 | 2019-05-28 | Photopill Medical Ltd. | Capsule phototherapy |
US10357661B2 (en) | 2011-09-30 | 2019-07-23 | Percuvision, Llc | Medical device and method for internal healing and antimicrobial purposes |
WO2014147497A1 (en) * | 2013-03-19 | 2014-09-25 | Medlight S.A. | Medical device for illuminating cavities of complex shapes |
IT201600129679A1 (en) * | 2016-12-21 | 2018-06-21 | Probiomedica S R L | Ingestible capsule for the phototherapeutic treatment of infections |
WO2018116216A1 (en) * | 2016-12-21 | 2018-06-28 | Probiomedica S.R.L. | Ingestible capsule for the phototherapeutic treatment of infections |
CN110087727A (en) * | 2016-12-21 | 2019-08-02 | 普罗比奥梅迪卡公司 | Capsule of eating for phototherapy treatment infection |
CN110087727B (en) * | 2016-12-21 | 2021-04-20 | 普罗比奥梅迪卡公司 | Swallowable capsule for phototherapy treatment of infections |
US11331514B2 (en) | 2016-12-21 | 2022-05-17 | Probiomedica S.R.L. | Ingestible capsule for the phototherapeutic treatment of infections |
Also Published As
Publication number | Publication date |
---|---|
EP2496306A1 (en) | 2012-09-12 |
EP2496306B1 (en) | 2014-01-15 |
US20120226335A1 (en) | 2012-09-06 |
US9138593B2 (en) | 2015-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9138593B2 (en) | Ingestible capsule for treating gastric infections, in particular for treating H. pylori infections | |
ES2552662T3 (en) | Irradiation device | |
ES2849431T3 (en) | Ingestible capsule for the phototherapeutic treatment of infections | |
RU2108122C1 (en) | Method and device for physiotherapeutic irradiation with light | |
US20040039242A1 (en) | Apparatus and methods using visible light for debilitating and/or killing microorganisms within the body | |
CN104080515B (en) | Irradiation devices | |
JP2012515003A5 (en) | ||
Tortora et al. | An ingestible capsule for the photodynamic therapy of helicobacter pylori infection | |
KR100893761B1 (en) | A light treatment apparatus for capsule type | |
CN111111014A (en) | Phototherapy capsule and phototherapy capsule kit | |
CN110432867A (en) | A kind of smooth power diagnosis and treatment one capsule endoscope | |
CN210786005U (en) | Disposable luminous capsule | |
CN219270872U (en) | Phototherapy type electronic endoscope for treating helicobacter pylori infection | |
CN110267708A (en) | Endoscope apparatus and the endoscope inspection method for utilizing endoscope apparatus | |
US20230067979A1 (en) | An ingestible therapeutic device for the treatment of gastritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09820080 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 13508195 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009820080 Country of ref document: EP |